In addition to the FDA-approved three compounds, several other CDK4/6 inhibitors are being explored, with ongoing clinical studies evaluating their effect on their own or in combination with other targeted therapies as standard chemotherapies in BC. This evidence concerns the gene CDK4 and breast cancer.